Clinical Trials About "Which Came First Cannabis Psychotic Disorders Scientists Weigh" RSS

05:08 EDT 20th March 2019 | BioPortfolio

We list hundreds of Clinical Trials about "Which Came First Cannabis Psychotic Disorders Scientists Weigh" on BioPortfolio. We draw our references from global clinical trials data listed on and refresh our database daily.

More Information about "Which Came First Cannabis Psychotic Disorders Scientists Weigh" on BioPortfolio

We have published hundreds of Which Came First Cannabis Psychotic Disorders Scientists Weigh news stories on BioPortfolio along with dozens of Which Came First Cannabis Psychotic Disorders Scientists Weigh Clinical Trials and PubMed Articles about Which Came First Cannabis Psychotic Disorders Scientists Weigh for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Which Came First Cannabis Psychotic Disorders Scientists Weigh Companies in our database. You can also find out about relevant Which Came First Cannabis Psychotic Disorders Scientists Weigh Drugs and Medications on this site too.

Showing "Which Came First Cannabis Psychotic Disorders Scientists Weigh" Clinical Trials 1–25 of 5,900+

Extremely Relevant

Facilitating the Behavioral Treatment of Cannabis Use Disorder

Cannabis use disorders remain a significant public health problem. The pharmacological facilitation of behavioral treatment represents a promising strategy for addressing disordered cannabis use. Cannabis use disorders are recognized to be associated with various vulnerabilities that complicate the course of treatment and that may be amenable to glutamate modulators. The purpose of this randomized, double-blind, controlled trial is to test various glutamate modulators in conjun...

Substance Misuse To Psychiatric Disorders for Cannabis

With the recent availability of vortioxetine, and the surging phenomenon of cannabis misuses amongst young abusers, it is a timely opportunity to conduct an early pharmacotherapy intervention study to offer an evidence-based strategy aiming to stop individuals with cannabis use disorders with depressive or anxiety symptoms, to develop into a more chronic disabling dependence or co-morbid state.

Treatment of MDEs During the Course of Psychotic Disorders With Duloxetine

We evaluate the efficacy and tolerability of duloxetine in the treatment of major depressive episodes during the course of psychotic disorders


Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia

Cannabis use disorders are an important public health problem in the United States, but no effective pharmacotherapies are available to treat these disorders. People with schizophrenia are more likely than healthy people to abuse cannabis. Cannabis use may worsen clinical outcomes in this group, making the identification of pharmacotherapy to treat cannabis dependence in those with schizophrenia important. The investigators intend to test the combination of dronabinol, a cann...

Quetiapine in the Treatment of Psychotic Depression - a Pilot Study

Atypical antipsychotics have been found not only to be beneficial in the treatment of psychotic disorders, but even for depressive symptoms in patients with schizophrenia. Remarkably, preliminary data suggest that the atypical antipsychotic quetiapine has antidepressive properties. Until now, there is limited knowledge concerning the efficacy of quetiapine in major depressive illness and especially in psychotic depression. In our own clinical practice, several patients with psy...

Screening for Childhood-Onset Psychotic Disorders

The purpose of this study is to screen and evaluate children with psychotic disorders to establish or confirm their diagnosis and to collect data about their condition. This study will also recruit individuals for various treatment studies. Childhood psychotic disorders are debilitating conditions in which children have auditory or visual hallucinations and disorganized thoughts. This study will examine psychotic disorders in children in an inpatient setting. Participan...

Resistance Exercise and Cannabis Use

Cannabis is the most widely used illicit drug and rates of hazardous use, and cannabis use disorders (CUDs), have continued to rise in recent years. The highest rates of use and CUDs are seen in young adults (20 - 24 years old) with more than 50% of young adults reporting lifetime use of cannabis, 35% report use in the past year, and 20% report use in the past month. Increased exposure produces higher risk for detrimental psychological and behavioral effects of cannabis use. Gi...

Nabilone in Cannabis Users With PTSD

Despite the prevalence of cannabis use among the PTSD population and self-reports that it is used to help cope with PTSD symptoms, the direct effects of cannabis on PTSD symptomology are unknown. The purpose of this placebo-controlled, within-subject study is to assess the effects of smoked cannabis and orally administered nabilone, a synthetic analog of THC, the primary psychoactive component of cannabis on multiple dimensions of PTSD symptomatology in cannabis smokers with PT...

Dose-response of Cannabis and Driving

Epidemiological studies have established a link between collisions while driving and cannabis use. With the changing legal landscape around cannabis, there is much interest in determining per se limits of cannabis while driving. The present study will evaluate driving on a driving simulator after smoking placebo or cannabis with 3 different levels of THC. THC is the active component in cannabis and blood, urine and oral fluid levels of THC will be correlated with driving impair...

Cannabis Use and Epigenetic Alterations in Human Male Sperm Cells

This is a follow-up project to a proof-of-concept study to determine if Cannabis use in male humans is associated with changes in DNA methylation profile of sperm. This proposal will examine the epigenome of sperm from men actively using Cannabis before and after a period of Cannabis abstinence. The results will be compared to control non-users.

The Effect of Cannabis on Dementia Related Agitation and Aggression

The most common syndrome in patients with severe dementia is agitated behavior, which is often characterized by a combination of violent behavior (physical or verbal), restlessness, and inappropriate loudness. The treatment options for this syndrome are limited and lead to severe side effects. In vivo experiments on animals and clinical studies on adults show that cannabinoids could have a beneficial effect on behavioral disorders in general, and in dementia-related disorders i...

Detection of Cannabis Impairment With an Eye Tracker

Cannabis is one of the widely used psychoactive substances in the world. With increasing legalization, the prevalence of driving under the influence of cannabis will undoubtedly rise. At present, roadside detection of cannabis intoxication is largely dependent on drug recognition experts who rely on changes in eye movements when impaired. In this regard, use of eye trackers can help to detect impairment in drivers. The purpose of the present study is to determine the feasibilit...

Progesterone for Cannabis Withdrawal

Sex and gender differences in behavioral, biological, and clinical correlates of substance use disorders are myriad, yet there exists a dearth of gender-informed treatment options. Ovarian hormones have been identified as potential mechanisms of these disparities , and recent clinical trials have begun to examine their utility as possible pharmacotherapeutic agents. The ovarian hormone progesterone has shown promise as a treatment for female cocaine and nicotine users, but has ...

Tracking Service Use and Outcomes II:First Episode Psychosis and Psychotic Disorders Clinic

Main Research questions: 1. Who are the patients referred for treatment at the Psychotic Disorders Clinic? 2. What are the outcomes from treatment for first episode psychosis in multiple outcome domains? 3. What hospital resources are used over the early course of the illness? 4. How satisfied are patients and family with the treatment and services they received? This is an important study that will help us evaluate the service and treatment offered ...

rTMS Treatment for Cannabis Use Disorders in Psychosis

Cannabis use during adolescence represents a significant risk factor for the development of psychosis including schizophrenia. Moreover, cannabis is the most commonly used drug among patients with an existing psychotic disorder. An estimated 25% of patients with psychosis reportedly meet the criteria of a cannabis use disorder particularly among younger patients experiencing their first episode. Cannabis use significantly exacerbates symptomatology resulting in an increased dur...

Effect of Lorcaserin on Cannabis Withdrawal and Self-administration

In this study, the investigators are interested in testing how lorcaserin influences the effects of cannabis in a human laboratory model of cannabis use.

The Role of Dysmyelination in Cognitive Impairment of Psychotic Spectrum Disorders

This is a single center comparative between-group study and correlational analyses to establish biomarkers of dysmyelination and cognitive impairment in Psychotic Spectrum Disorders using imaging, neuropsychological, and genetic assays.The study will provide non-invasive biomarkers of cognitive dysfunction in Psychotic Spectrum Disorder.

Effects of Cannabis on Prescription Drug Abuse Liability and Analgesia

The purpose of this research is to assess the impact of cannabis on the analgesic and abuse-liability effects of a sub-threshold dose of a commonly used analgesic.

Treatment of Psychotic Major Depression With Mifepristone

The purpose of this research study is to see how certain hormones cause changes in mood and thinking in some depressed patients and to determine the effectiveness of mifepristone in treating some forms of depression. This study is conducted in conjunction with an observational study "Clinical and Biological Characteristics of Psychotic Depression".

Ketogenic Diet for Psychotic Disorders - A PsyDiet Pilot Study

Disturbances in glucose metabolism and glutamate neurotransmission feature in the pathophysiology of psychotic disorders. Ketogenic diet (KD) is a high-fat, low-carbohydrate diet that restricts glucose and forces metabolism of ketones, which serve as alternative energy substrates for the brain. KD is an established treatment for intractable epilepsy. However, we lack the randomized controlled trials (RCT) evidence regarding potential effects of KD on psychotic symptoms in human...

Using Implementation Intentions to Reduce Cannabis Use

The study will recruit frequent users of cannabis (defined at least fortnightly use) and randomize them either to: (1) form implementation intentions by linking situations in which they are tempted to use cannabis with strategies to avoid using cannabis in those situations by using a volitional help sheet, or (2) to consider the situations in which they are tempted to use cannabis alongside possible strategies to avoid using it as presented in the volitional help sheet but not ...

Pharmacogenetics of Cannabinoid Response

Background: Cannabis is one of the most commonly used and abused illicit substances, and may produce harmful effects in some individuals. Epidemiological data suggest that cannabis use is associated with a modest risk for the emergence of psychosis and psychotic disorders. In laboratory studies, we have shown that Delta-9-tetrahydrocannabinol (Δ-9-THC) induced transient but clinically significant psychotomimetic and amnestic effects in some but not all carefully screened hea...

Investigation of Cannabis for Chronic Pain and Palliative Care

The use of cannabis for severe medical conditions is being legalized in different states, increasing the mandate to make cannabis legal for medically ill patients. However, there is a lack of placebo-controlled studies investigating the efficacy of cannabis. Dronabinol (synthetic, oral Δ-9-THC) is FDA approved for the appetite stimulation in AIDS-related anorexia and nausea/vomiting in chemotherapy patients. Nabilone, a synthetic analogue of THC, is approved for nausea/vomitin...

Pharmacokinetic and Pharmacodynamic Effects of Smoked and Vaporized Cannabis

Few studies have been conducted to assess the pharmacokinetic and pharmacodynamic effects of smoked and vaporized cannabis. Careful analysis of different cannabis administration methods on these parameters is required to determine the level and duration of biological cannabinoid exposure and associated subjective, cardiovascular and cognitive effects. In the present study the investigators evaluated the detection of cannabinoids in whole blood, oral fluid, and urine, as well as...

Clinical Trial Tobacco Marijuana

Approximately 50% of persons seeking treatment for cannabis-use disorders (CUDs) regularly smoke tobacco. Combining tobacco with cannabis has become a common method of smoking cannabis. Similarities of use, and using together, can make quitting difficult. Stopping tobacco simultaneously with cannabis may be beneficial. Little scientific information currently addresses how to best target tobacco smoking during treatment for CUDs. Our long-term goal is to develop an effective pro...

More From BioPortfolio on "Which Came First Cannabis Psychotic Disorders Scientists Weigh"

Quick Search